Search
Somatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigationalGrowth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigational[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalEncorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnSerdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia.
Estrone
go.drugbank.com/drugs/DB00655ApprovedEstrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
Pirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnIt is generally well tolerated by patients.
Laronidase
go.drugbank.com/drugs/DB00090ApprovedInvestigationalHuman recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.
Products: ALDURAZYME 100 U/ML IV INFUZYON ICIN KONSANTRE COZELTI, 1 ADETPeginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalApproved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label]. … Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors.
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalIt was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. … Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by
Clopamide
go.drugbank.com/drugs/DB13792InvestigationalLike thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.